Article
Retinoic acid receptor alpha drives cell cycle progression and is associated with increased sensitivity to retinoids in T-cell lymphoma.
Oncotarget - 18 Apr 2017
Wang Xueju, Dasari Surendra, Nowakowski Grzegorz S, Lazaridis Konstantinos N, Wieben Eric D, Kadin Marshall E, Feldman Andrew L, Boddicker Rebecca L
Abstract excerpt
Peripheral T-cell lymphomas (PTCLs) are aggressive non-Hodgkin lymphomas with generally poor outcomes following standard therapy. Few candidate therapeutic targets have been identified to date. Retinoic acid receptor alpha (RARA) is a transcription factor that modulates cell growth and differentiation in response to retinoids. While retinoids have been used to treat some cutaneous T-cell lymphomas (CTCLs), their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.